Adalimumab for the treatment of Crohn's disease

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 763-777

  Cassinotti, Andrea ^a   Ardizzone, Sandro ^a   Porro, Gabriele Bianchi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adalimumab; Anti TNF; Biologics; Crohn's disease; Treatment

Indexed keywords

EID: 70349486726     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Anderson PJ. 2005. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum, 34:19-22.
2. Anwar M, O'Sullivan M, Ryan B, et al. 2006. An open label study of adalimumab in Crohn's disease patients with a loss of response to infliximab [abstract]. Gastroenterology, 130(Suppl 2):A-662(abstr W1225).
3. Ardizzone S, Bianchi Porro G. 2002. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med, 252:4675-96.
4. Ardizzone S, Bianchi Porro G. 2005. Biologic therapy for inflammatory bowel disease. Drugs, 65:2253-86.
5. Baert F, Norman M, Vermeire S, et al. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med, 348:601-8.
6. Baumgart DC, Carding SR. 2007. Inflammatory bowel disease: cause and immunobiology. Lancet, 369:1627-40.
7. Baumgart DC, Sandborn WJ. 2007. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 369:1641-57.
8. Best WR, Becktel JM, Singleton JW, et al. 1976. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology, 70:439-44.
9. Beuthien W, Mellinghoff HU, von Kempis J. 2004. Skin reaction to adalimumab. Arthritis Rheum, 50:1690-2.
10. Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295:2275-85.
11. Boura P, Sarantopoulos A, Lefaki I, et al. 2006. Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab. Ann Rheum Dis, 65:839-40.
12. Braegger CP, Nicholls S, Murch SH, et al. 1992. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 339:89-91.
13. Breedveld FC. 2000. Therapeutic monoclonal antibodies. Lancet, 355:735-40.
14. Breese E, McDonald TT. 1995. TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol, 371:821-4.
15. Bressler B. 2007. Adalimumab in Crohn's disease. Biodrugs, 21:133-4.
16. Burmester GR, Panaccione R, Kent JD, et al. 2006. Adalimumab safety in Crohn's disease and rheumatoid arthritis clinical trials, reduced mortality in rheumatoid arthritis [abstract]. Am J Gastroenterol, 101(Suppl 9):452-3(abstr 1160).
17. Cassinotti A, Annaloro C, Ardizzone S, et al. 2008. Autologous haematopoietic stem cell transplantation without CD34hhhhhhhhhhhhhcell selection in refractory Crohn's disease. Gut, 57:211-7.
18. Chaudhary R, Butler M, Playford RJ, et al. 2006. Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to infliximab and adalimumab at 10 micrograms per ml concentration. Gastroenterology, 130:A696.
19. Coburn LA, Wise PE, Schwartz DA. 2006. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci, 51:2045-7.
20. Colombel JF, Sandborn WJ, Reinisch W, et al. 2007b. Adalimumab safety in Crohn's disease trials. Gastroenterology, 132(Suppl 2):A-504.
21. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. 2007a. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology, 132:52-65.
22. Davis MK, Rufo PA, Polyak SF, et al. 2008. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J Inherit Metab Dis. [Epub ahead of print] PMID: 18172743.
23. Deslandres C, Faure C, Dirks MH, et al. 2006. Open label experience in adalimumab in pediatric Crohn's disease patients who lost response or were intolerant to infliximab [abstract no. W1199]. Gastroenterology, 130(Suppl 2):A-656.
24. Di Sabatino A, Pender SL, Jackson CL, et al. 2007. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology, 133:137-49.
25. Farrell RJ, Alsahli M, Jeen YT, et al. 2003. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology, 124:917-24.
26. Furst DE, Schiff MH, Fleischmann RM, et al. 2003. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol, 30:2563-71.
27. Garimella TS, Peng JZ, Beck K, et al. 2006. Pharmacokinetics of adalimumab in a long-term investigation of the induction and maintenance of remission in patients with Crohn's disease (CLASSIC I and CLASSIC II) [abstract]. Gastroenterology, 130(Suppl 2):A-481(abstr T1133).
28. Granneman RG, Zhang Y, Noertersheuser PA, et al. 2003. Pharmacokinetic/ pharmacodynamic (PK/ PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. Arthritis Rheum, 48:S140, S1.
29. Hadziselimovic F. 2008. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease. J Pediatr Gastroenterol Nutr, 46:208-11.
30. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. 2006. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology, 130:323-33.
31. Hanauer SB, Wagner CL, Bala M, et al. 2004. Incidence and importance of antibody response to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol, 2:542-53.
32. Hinojosa J, Gomollon F, Garcìa S, et al. 2007. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther, 25:409-18.
33. Ho GT, Smith L, Aitken S, et al. 2008. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther, 27:308-15.
34. Kaine JL, Kivitz AJ, Birbara C, et al. 2007. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol, 34:272,9.
35. Kaplan GG, Hur C, Korzenik J, et al. 2007. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a costeffectiveness analysis. Aliment Pharmacol Ther, 26:1509-20.
36. Kavanaugh AF, Greenwald M, Zizic T, et al. 2002. Treatment with adalimumab (D2E7) does not affect normal immune responsiveness. Arthritis Rheum, 46:S132.
37. Korzenik J. 2007. Adalimumab in Crohn's disease. Biodrugs, 21:133-4.
38. Kwon HJ, Cote TR, Cuffe MS et al. 2003. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med, 138:807-11.
39. Lester MA, Dit Dinard BM, Pagenault M, et al. 2005. Treatment of Crohn's disease by adalimumab anti-TNF monoclonal antibody in an infliximab-allergic patient [abstract no. PT-186]. Pharm World Sci, 27:A98.
40. Mannon P. 2007. GAIN for loss: adalimumab for infliximab-refractory Crohn disease. Ann Intern Med, 146:888-90.
41. Manosa M, Domènech E, Marín L, et al. 2008. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab. Gut, 57:559.
42. Mian S, Baron H. 2005. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr, 41:357-9.
43. Mishkin DS, Van Deinse W, Becker JM, et al. 2006. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis, 12:827-8.
44. Mitoma H, Horiuchi T, Tsukamoto H, et al. 2008. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells. Comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum, 58:1248-57.
45. Murch SH, Braegger CP, Walzer-Smith JA, et al. 1993. Localisation of tumor necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut, 34:1705-9.
46. Nesbitt A, Fossati G, Bergin M, et al. 2007. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis, 13:1323-32.
47. Nestorov I. 2004. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum, 34:12-8.
48. Panes J, Gomollon F, Taxonera C, et al. 2007. Crohn's disease: a review of current treatment with a focus on biologics. Drugs, 67:2511-37.
49. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. 2005. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol, 100:75-9.
50. Papadakis KA, Targan SR. 2000. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology, 119:1148-57.
51. Paulson SK, Noertersheuser P, Pollack PF, et al. 2005. Pharmacokinetics of adalimumab from Classic, a randomized phase 3 trial for the induction of clinical remission in patients with Crohn's [abstract]. Gastroenterology, 128(Suppl 2):A-585(abstr W1057).
52. Peppelenbosch MP. 2007. Adalimumab in Crohn's disease. Biodrugs, 21:134.
53. Perez JL, Kupper H, Spencer-Green JT. 2005. Impact of screening for latent TB prior to initiating anti-TNF therapy in North America and Europe. Abstract OP0093. Annual European Congress of Rheumatology (EULAR), Vienna, Austria 2005.
54. Peyrin-Biroulet L, LaClotte C, Bigard MA. 2006. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther, 25:675-80.
55. Plosker GL, Lyseng-Williamson KA. 2007. Adalimumab. In Crohn's Disease. Biodrugs, 21:125-32.
56. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. 2007. Autoimmune diseases induced by TNF-targeted therapies. Analysis of 233 cases. Medicine, 86:242-51.
57. Reinecker HC, Steffen M, Witthoeft T, et al. 1993. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol, 94:174-81.
58. Saliu OY, Sofer C, Stein DS, et al. 2006. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis, 194:486-92.
59. Sandborn WJ, Hanauer S, Loftus EV Jr., et al. 2004. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol, 99:1984-9.
60. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. 2007b. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut, Epub Feb 13. PMID: 17299059.
61. Sandborn WJ, Rutgeerts P, Enns R, et al. 2007a. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med. Ann Intern Med, 146:829-38.
62. Santora LC, Kaymakcalan Z, Sakorafas P, et al. 2001. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem, 299:119-29.
63. Scallon B, Cai A, Solowski N, et al. 2002. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther, 301:418-26.
64. Scheinfeld N. 2005. Adalimumab: a review of side effects. Expert Opin Drug Saf, 4:637-41.
65. Schiff MH, Burmester GR, Kent JD, et al. 2006. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis, 65:889-94.
66. Seiderer J, Brand S, Dambacher J, et al. 2007. Adalimumab in patients with Crohn's disease-safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther, 25:787-96.
67. Shen C, Assche GV, Colpaert S, et al. 2005. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther, 21:251-8.
68. Shen C, Van Assche G, Rutgeerts P, et al. 2006. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric Gastroenmouse model. Inflamm Bowel Dis, 12:22-8.
69. Stallmach A, Giese T, Schmidt C, et al. 2004. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab-report of a case. Eur J Gastroenterol Hepatol, 16:627-30.
70. Tracey D, Klareskog L, Sasso EH, et al. 2008. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Therap, 117:244-79.
71. Travis SP, Stange EF, Lemann M, et al. 2006. European Crohn's and Colitis Organisation. European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. Gut, 55(Suppl 1):i16-i35.
72. Vesga L, Terdiman JP, Mahadevan U. 2005. Adalimumab use in pregnancy. Gut, 54:890.
73. Vigna-Pérez M, Abud MC, Portillo SH, et al. 2005. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol, 141:372,80.
74. Youdim A, Vasiliauskas EA, Targan SR, et al. 2004. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis, 10:333-8.